What is the expected cost of the Phase Ib/2a trial and its impact on Lantern Pharma’s cash runway and financing needs? | LTRN (Aug 06, 2025) | Candlesense
LTRN

What is the expected cost of the Phase Ib/2a trial and its impact on Lantern Pharma’s cash runway and financing needs?

The press release you referenced announces that the U.S. Food and Drug Administration has cleared Starlight Therapeutics’ IND for a Phase Ib/2a study of STAR‑001 (LP‑184) plus spironolactone in patients with glioblastoma multiforme. However, the release does not contain any details about the expected cost of the trial, nor does it discuss how the trial’s expense will affect Lantern Pharma’s cash runway or future financing requirements.

Because the article you provided does not disclose those financial figures, I’m unable to give a concrete answer about the trial’s budget or its impact on the company’s liquidity. If Lantern Pharma releases additional information—such as a financial press release, earnings call transcript, or SEC filing that outlines trial spend, cash balances, or financing plans—that material would allow a more complete analysis. Until such data become publicly available, the cost and cash‑flow implications of the Phase Ib/2a GBM trial remain unspecified.

Other Questions About This News

What is the anticipated timeline for enrollment and data read‑out from the Phase Ib/2a GBM trial? How does this trial program compare to competitor pipelines targeting GBM or other CNS indications? What potential regulatory or safety challenges could delay or jeopardize the trial’s progression? How might the partnership or licensing structure (if any) for STAR‑001 affect future revenue streams or margin assumptions? How will the FDA clearance for the IND affect Lantern Pharma’s short‑term stock price? Will the trial results be disclosed in upcoming investor presentations or conference calls, and what impact could that have on market perception? What are the projected market size and commercial upside if the combination therapy receives eventual approval? How does STAR‑001 (LP‑184) in combination with spironolactone compare to existing GBM treatments in terms of mechanism and potential efficacy? What enrollment criteria and patient population size are required for the trial, and how might that influence trial risk?